{"id":32165,"date":"2021-02-23T09:50:06","date_gmt":"2021-02-23T14:50:06","guid":{"rendered":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/?p=32165"},"modified":"2021-02-23T09:50:06","modified_gmt":"2021-02-23T14:50:06","slug":"bhbp-biotech-firms-starts-covid-19-vaccine-trials","status":"publish","type":"post","link":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/2021\/02\/23\/bhbp-biotech-firms-starts-covid-19-vaccine-trials\/","title":{"rendered":"BHBP Biotech Firms Starts COVID-19 Vaccine Trials"},"content":{"rendered":"<p style=\"margin: 0in;margin-bottom: .0001pt;line-height: 16.2pt\"><span class=\"xbumpedfont15\"><span style=\"font-size: 13.5pt\">Codagenix,\u00a0<span style=\"color: #1d2228\">the\u00a0clinical-stage biotechnology company\u00a0located at the <\/span><\/span><\/span><span class=\"xbumpedfont15\"><span style=\"font-size: 13.5pt;color: #1d2228\">Broad<\/span><\/span> <span class=\"xbumpedfont15\"><span style=\"font-size: 13.5pt;color: #1d2228\">Hollow<\/span><\/span> <span class=\"xbumpedfont15\"><span style=\"font-size: 13.5pt;color: #1d2228\">Bioscience<\/span><\/span> <span class=\"xbumpedfont15\"><span style=\"font-size: 13.5pt;color: #1d2228\">Park<\/span><\/span><span class=\"xbumpedfont15\"><span style=\"font-size: 13.5pt;color: #1d2228\"> on campus, has started human trials of a COVID-19 vaccine it hopes to be able to commercialize beginning in 2022.<\/span><\/span><\/p>\n<p style=\"margin: 0in;margin-bottom: .0001pt;line-height: 16.2pt\"><span style=\"font-size: 13.5pt\">\u00a0<\/span><\/p>\n<p style=\"margin: 0in;margin-bottom: .0001pt;line-height: 16.2pt\"><span class=\"xbumpedfont15\"><span style=\"font-size: 13.5pt;color: #1d2228\">In addition, Codagenix has secured a <\/span><\/span><span class=\"xbumpedfont15\"><span style=\"font-size: 13.5pt;color: #1d2228\">U.S.<\/span><\/span><span class=\"xbumpedfont15\"><span style=\"font-size: 13.5pt;color: #1d2228\"> patent for a vaccine administered nasally to fight\u00a0respiratory syncytial virus, or RSV. \u00a0<\/span><\/span><\/p>\n<p style=\"margin: 0in;margin-bottom: .0001pt;line-height: 16.2pt\"><span style=\"font-size: 13.5pt\">\u00a0<\/span><\/p>\n<p style=\"margin: 0in;margin-bottom: .0001pt;line-height: 16.2pt\"><span class=\"xbumpedfont15\"><span style=\"font-size: 13.5pt;color: #1d2228\">Robert Coleman, PhD, an associate professor of Biology at FSC,\u00a0<\/span><\/span><span class=\"xbumpedfont15\"><span style=\"font-size: 13.5pt;color: #333333;background: white\">co-founded\u00a0Codagenix, Inc.\u00a0in 2012\u00a0to commercialize the genome design platform for vaccine development that he has previously co-invented.<\/span><\/span><\/p>\n<p style=\"margin: 0in;margin-bottom: .0001pt;line-height: 16.2pt\"><span style=\"font-size: 13.5pt\">\u00a0<\/span><\/p>\n<p class=\"xs9\" style=\"margin: 3.75pt 0in 3.75pt 0in\"><span class=\"xbumpedfont15\"><span style=\"font-size: 13.5pt\">Jeffrey Fu, chief business officer\u00a0of\u00a0Codagenix, told\u00a0<i>Newsday <\/i>that the first doses in the double-blind, placebo-controlled study were administered to volunteers in <\/span><\/span><span class=\"xbumpedfont15\"><span style=\"font-size: 13.5pt\">London<\/span><\/span><span class=\"xbumpedfont15\"><span style=\"font-size: 13.5pt\"> this month.<\/span><\/span><\/p>\n<p class=\"xs9\" style=\"margin: 3.75pt 0in 3.75pt 0in\"><span style=\"font-size: 13.5pt\">\u00a0<\/span><\/p>\n<p style=\"margin: 0in;margin-bottom: .0001pt;line-height: 16.2pt\"><span class=\"xbumpedfont15\"><span style=\"font-size: 13.5pt;color: #1d2228\">Last month, Codagenix secured the patent for a vaccine to fight RSV, a common respiratory virus that usually causes mild, cold-like symptoms. Many of those affected by RSV frequently recover within 7-14 days, but RSV remains a serious condition for certain populations. It can be especially serious for infants and older adults.\u00a0<\/span><\/span><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Codagenix,\u00a0the\u00a0clinical-stage biotechnology company\u00a0located at the Broad Hollow Bioscience Park on campus, has started human trials of a COVID-19 vaccine it hopes to be able to commercialize beginning in 2022. \u00a0 In addition, Codagenix has secured a U.S. patent for a vaccine administered nasally to fight\u00a0respiratory syncytial virus, or RSV. \u00a0 \u00a0 Robert Coleman, PhD, an [&hellip;]<\/p>\n","protected":false},"author":30,"featured_media":32198,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":[],"categories":[10],"tags":[],"_links":{"self":[{"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/posts\/32165"}],"collection":[{"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/users\/30"}],"replies":[{"embeddable":true,"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/comments?post=32165"}],"version-history":[{"count":1,"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/posts\/32165\/revisions"}],"predecessor-version":[{"id":32167,"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/posts\/32165\/revisions\/32167"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/media\/32198"}],"wp:attachment":[{"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/media?parent=32165"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/categories?post=32165"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/blogs.farmingdale.edu\/sites\/campus-times\/wp-json\/wp\/v2\/tags?post=32165"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}